Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2022 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") held on June 10, 2022, Regeneron's shareholders voted on the matters set forth below.

Proposal 1 - Election of Directors

The following nominees for Class I directors were elected to serve until the 2025 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:





Nominee                         For            Against          Abstain        Broker Non-Votes
Bonnie L. Bassler, Ph.D.      96,952,597       14,570,093        79,166               4,718,158
Michael S. Brown, M.D.        86,297,273       25,254,693        49,890               4,718,158
Leonard S. Schleifer,
M.D., Ph.D.                  110,095,873        1,462,796        43,187               4,718,158
George D. Yancopoulos,
M.D., Ph.D.                  109,522,953        1,977,542       101,361               4,718,158

Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm

The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022, was approved based upon the following votes:





For:     111,768,970
Against:   4,493,063
Abstain:      57,981

Proposal 3 - Advisory Vote on Executive Compensation

The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement was approved based on the following votes:





For:              97,837,229
Against:          13,595,339
Abstain:             169,288
Broker Non-Votes:  4,718,158

© Edgar Online, source Glimpses